Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol
2024

Better Outcomes with Osilodrostat for Cushing Disease

Sample size: 160 publication 10 minutes Evidence: high

Author Information

Author(s): John Newell-Price, Maria Fleseriu, Rosario Pivonello, Richard A. Feelders, Mônica R. Gadelha, André Lacroix, Przemysław Witek, Anthony P. Heaney, Andrea Piacentini, Alberto M. Pedroncelli, Beverly M. K. Biller

Primary Institution: University of Sheffield

Hypothesis

Does simultaneous normalization of late-night salivary cortisol and mean urinary free cortisol in patients with Cushing disease treated with osilodrostat lead to better clinical outcomes than controlling either parameter alone?

Conclusion

Normalizing both late-night salivary cortisol and mean urinary free cortisol in patients with Cushing disease treated with osilodrostat leads to improved long-term clinical outcomes.

Supporting Evidence

  • 85% of patients had uncontrolled cortisol levels at baseline.
  • 48.6% of patients achieved control of both LNSC and mUFC by week 72.
  • Patients with both LNSC and mUFC controlled showed greater improvements in cardiovascular parameters.
  • Quality of life improved significantly in patients with controlled cortisol levels.
  • Improvements in physical manifestations of hypercortisolism were observed regardless of cortisol control.

Takeaway

This study shows that for people with Cushing disease, getting both their nighttime and daily cortisol levels back to normal helps them feel better and stay healthier.

Methodology

Pooled data from two phase III osilodrostat studies were analyzed, focusing on changes in cardiovascular/metabolic parameters, physical manifestations, and quality of life across different patient subgroups.

Potential Biases

Interindividual variability in cortisol levels may affect results.

Limitations

The analysis had a small number of patients with LNSC control only and differences in osilodrostat exposure between studies.

Participant Demographics

{"median_age":39,"female_percentage":80.6,"race_distribution":{"Caucasian":64.4,"Asian":27.5,"Black":3.1,"Native American":0.6,"Other":2.5,"Unknown":1.9}}

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI for time to first normalization: LNSC 82.0 days, mUFC 35.0 days, both 335.0 days

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1210/jendso/bvae201

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication